Moreover, a DPP-IV inhibitor as an add-on to standard therapy has been shown to improve clinical outcomes, radiological scores, and inflammatory biomarkers compared to standard therapy in non-diabetic patients with COVID-19 [56]. This evidence concerns the gene DPP4 and COVID-19.